Showing 6861-6870 of 9115 results for "".
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- Upcoming Skin Cancer Champions Webinar Addresses Impact of AIhttps://practicaldermatology.com/news/Upcoming-Skin-Cancer-Champions-Webinar-Addresses-Impact-AI/2475627/Veronica Rotemberg, MD, PhD, will host a free webinar on the future of non-melanoma skin cancer care August 5 at 1:00 PM ET, Skin Cancer Champions announced. Dr. Rotemberg, Director of Dermatology Imaging Informatics for Memorial Sloan Kettering Cancer Center, will present “The Future of S
- Anaysis: Linperlisib and Chidamide Safe, Effective in Advanced CTCLhttps://practicaldermatology.com/news/anaysis-linperlisib-and-chidamide-safe-effective-in-advanced-ctcl/2475518/An investigational combination of linperlisib and chidamide demonstrated clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), according to results from a phase 1 trial. The single-arm, n
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Study: Sofpironium Gel Effective for Axillary Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-support-sofpironium-gel-for-axillary-hyperhidrosis/2475489/Sofpironium topical gel, 12.45%, showed efficacy and tolerability in treating primary axillary hyperhidrosis, according to pooled results from two pivotal Phase 3 trials. Researchers for the combined analysis of the Cardigan
- SKINVIVE sPMA Accepted for Neck Line Treatmenthttps://practicaldermatology.com/news/skinvive-spma-accepted-for-neck-line-treatment/2475452/The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental premarket approval (sPMA) application from Allergan Aesthetics, an AbbVie company, for SKINVIVE by JUVÉDERM® for the treatment of neck lines in adults, according to a press release.<
- ZORYVE Cream 0.15% Gets AAD Endorsement for Atopic Dermatitishttps://practicaldermatology.com/news/zoryve-cream-015-gets-aad-endorsement-for-atopic-dermatitis/2475411/The American Academy of Dermatology (AAD) has issued a strong recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adult patients with mild to moderate atopic dermatitis (AD), according to updated guidelines released June 26.
- Review: Air Quality and Weather Linked to Dermatitis Severityhttps://practicaldermatology.com/news/review-air-quality-and-weather-linked-to-dermatitis-severity/2475392/Increased exposure to air pollutants and extreme temperatures is associated with greater population burden of atopic dermatitis (AD), according to a systematic review published in JAMA Dermatology.
- New Data for Lebrikizumab and Tildrakizumab Unveiled at ICD 2025https://practicaldermatology.com/news/new-data-for-lebrikizumab-and-tildrakisumab-unveiled-at-icd-2025/2475320/New real-world and clinical data supporting the use of lebrikizumab in atopic dermatitis (AD) and tildrakizumab in psoriasis was recently presented at the XIV International Congress of Dermatology (ICD) in Rome, according to a press release from Almirall.
- New Biomarkers Linked to Atopic Dermatitis Severityhttps://practicaldermatology.com/news/new-biomarkers-linked-to-atopic-dermatitis-severity/2475296/New data published in JID Innovations shows elevated levels of immune cells in patients with atopic dermatitis (AD).